Kai Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kai Zhang has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Jia Zhong
Department of Anesthesiology and Intensive Care, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 shared publicationsMengcao Weng
Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
4 shared publications- Xiangming Fang
Department of Anesthesiology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
4 shared publications Yan Zhang
Department of Clinical Research Center, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
4 shared publicationsMinyue Qian
Department of Anesthesiology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, People’s Republic of China
3 shared publications- Yue Jin
Department of Anesthesiology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
3 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
Medial Prefrontal Cortex Modulation of the Peripheral Immune Response in Sepsis Via the Autonomic Nervous System
BACKGROUND: Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection, in which neuroimmune dysfunction plays a central role. The medial prefrontal cortex (mPFC) is involved in autonomic and immune regulation. However, its role in modulating peripheral immune responses during sepsis remains unclear. This study investigated whether glutamatergic neurons in the mPFC regulate systemic inflammation and organ injury during sepsis via autonomic pathways and adrenergic signaling. METHODS: Glutamatergic neurons in the mPFC were selectively manipulated using optogenetic activation or chemogenetic inhibition. Mice were assigned to four main groups: ChR2 (optogenetic activation), mCherry (optogenetic control), hM4Di (chemogenetic inhibition), and EGFP (chemogenetic control). Sepsis was then induced by intraperitoneal injection of Escherichia coli or by cecal ligation and puncture. Serum and splenic cytokines were quantified by enzyme-linked immunosorbent assay (ELISA), organ injury was assessed histologically, and splenic immune cell populations and macrophage polarization were analyzed by flow cytometry. Left cervical vagotomy (LcVGX), β2-adrenergic receptor (ADRB2) antagonism (ICI-118,551), and splenic denervation via 6-hydroxydopamine (6-OHDA) were applied to explore underlying mechanisms. RESULTS: Sepsis significantly activated mPFC neurons. Optogenetic activation of mPFC glutamatergic neurons reduced proinflammatory cytokine levels and attenuated liver, kidney, and lung injury, whereas chemogenetic inhibition exacerbated systemic inflammation and organ damage. Mechanistically, activation of mPFC neurons promoted macrophage polarization toward the M2 phenotype, whereas inhibition shifted polarization toward the M1 phenotype. LcVGX abolished the anti-inflammatory effects of mPFC activation (percentage of M2 macrophages: ChR2-sham vs mCherry-sham, mean ± SEM 19.4 ± 0.87% vs 14.4 ± 1.15%, P = .023; ChR2-LcVGX vs mCherry-LcVGX, mean ± SEM 14.0 ± 0.89% vs 14.2 ± 1.33%, P > .999; n = 5/group), indicating vagal dependence. Additionally, chemogenetic inhibition increased ADRB2 expression in the spleen, and ADRB2 blockade or splenic denervation reversed the proinflammatory macrophage polarization (percentage of M1 macrophages: hM4Di-saline vs EGFP-saline, mean ± SEM 30.8 ± 1.71% vs 23.0 ± 1.06%, P = .030; hM4Di-ICI-118,551 vs EGFP-ICI-118,551, mean ± SEM 20.9 ± 2.04% vs 21.6 ± 2.14%, P = .992; hM4Di-6-OHDA vs EGFP-6-OHDA, mean ± SEM 26.3 ± 3.00% vs 26.2 ± 2.34%, P > .999; n = 4/group). CONCLUSIONS: Glutamatergic neurons in the mPFC play a critical role in regulating peripheral immune responses during sepsis. The mPFC influences macrophage polarization, systemic inflammation, and organ injury via autonomic pathways involving the vagus and splenic nerves and ADRB2-dependent signaling. Targeting mPFC-mediated neuroimmune pathways may represent a potential therapeutic strategy for sepsis.
- 3 September 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
Open AccessMedial Prefrontal Cortex Modulation of the Peripheral Immune Response in Sepsis Via the Autonomic Nervous System
BACKGROUND: Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection, in which neuroimmune dysfunction plays a central role. The medial prefrontal cortex (mPFC) is involved in autonomic and immune regulation. However, its role in modulating peripheral immune responses during sepsis remains unclear. This study investigated whether glutamatergic neurons in the mPFC regulate systemic inflammation and organ injury during sepsis via autonomic pathways and adrenergic signaling. METHODS: Glutamatergic neurons in the mPFC were selectively manipulated using optogenetic activation or chemogenetic inhibition. Mice were assigned to four main groups: ChR2 (optogenetic activation), mCherry (optogenetic control), hM4Di (chemogenetic inhibition), and EGFP (chemogenetic control). Sepsis was then induced by intraperitoneal injection of Escherichia coli or by cecal ligation and puncture. Serum and splenic cytokines were quantified by enzyme-linked immunosorbent assay (ELISA), organ injury was assessed histologically, and splenic immune cell populations and macrophage polarization were analyzed by flow cytometry. Left cervical vagotomy (LcVGX), β2-adrenergic receptor (ADRB2) antagonism (ICI-118,551), and splenic denervation via 6-hydroxydopamine (6-OHDA) were applied to explore underlying mechanisms. RESULTS: Sepsis significantly activated mPFC neurons. Optogenetic activation of mPFC glutamatergic neurons reduced proinflammatory cytokine levels and attenuated liver, kidney, and lung injury, whereas chemogenetic inhibition exacerbated systemic inflammation and organ damage. Mechanistically, activation of mPFC neurons promoted macrophage polarization toward the M2 phenotype, whereas inhibition shifted polarization toward the M1 phenotype. LcVGX abolished the anti-inflammatory effects of mPFC activation (percentage of M2 macrophages: ChR2-sham vs mCherry-sham, mean ± SEM 19.4 ± 0.87% vs 14.4 ± 1.15%, P = .023; ChR2-LcVGX vs mCherry-LcVGX, mean ± SEM 14.0 ± 0.89% vs 14.2 ± 1.33%, P > .999; n = 5/group), indicating vagal dependence. Additionally, chemogenetic inhibition increased ADRB2 expression in the spleen, and ADRB2 blockade or splenic denervation reversed the proinflammatory macrophage polarization (percentage of M1 macrophages: hM4Di-saline vs EGFP-saline, mean ± SEM 30.8 ± 1.71% vs 23.0 ± 1.06%, P = .030; hM4Di-ICI-118,551 vs EGFP-ICI-118,551, mean ± SEM 20.9 ± 2.04% vs 21.6 ± 2.14%, P = .992; hM4Di-6-OHDA vs EGFP-6-OHDA, mean ± SEM 26.3 ± 3.00% vs 26.2 ± 2.34%, P > .999; n = 4/group). CONCLUSIONS: Glutamatergic neurons in the mPFC play a critical role in regulating peripheral immune responses during sepsis. The mPFC influences macrophage polarization, systemic inflammation, and organ injury via autonomic pathways involving the vagus and splenic nerves and ADRB2-dependent signaling. Targeting mPFC-mediated neuroimmune pathways may represent a potential therapeutic strategy for sepsis.
- Open Access
- 9 June 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-12
Causality of genetically predicted solid cancers on risk of sepsis: insights from Mendelian randomization
Objective Some studies have found that solid cancer and sepsis are linked. The primary objective of this study is to explore this connection further, investigating the causal effect of solid cancer on sepsis by applying Mendelian randomization (MR). Methods Using genome-wide association study (GWAS) data from the Medical Research Council-Integrative Epidemiology Unit database, we conducted a bidirectional two-sample Mendelian randomization (MR) analysis to test the causal association between solid cancers (10 GWAS, 1,345,730 samples) and sepsis (2 GWAS, 1,288,566 samples) in European ancestry. In the context of multivariable MR analysis, lifestyle risk factors such as body mass index (BMI) were incorporated, with relevant clinical interventions taken into account. Results The two-sample MR analysis suggested a causal relationship between renal cancer and sepsis (OR = 1.051, 95% CI = 1.019–1.085, PIVW = 1.800E-03). Renal cancer (OR = 1.064, 95% CI = 1.011–1.120, PIVW = 1.60E-02), BMI (OR = 1.315, 95% CI = 1.176–1.471, PIVW = 1.25E-06), and smoking (OR = 1.139, 95% CI = 1.009–1.286, PIVW = 3.65E-02) showed a significant association with sepsis in our lifestyle multivariable MR analysis. Reverse MR analysis indicates that sepsis may prevent renal cancer. (OR = 0.924, 95% CI = 0.865 -0.988, PIVW = 2.060E-02). Conclusions Our findings suggest renal cancer is correlated with the occurrence of sepsis. This association is partially influenced by BMI and smoking. Unexpectedly, sepsis may act as a protective effect against renal cancer.
- 9 June 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-12
Open AccessCausality of genetically predicted solid cancers on risk of sepsis: insights from Mendelian randomization
Objective Some studies have found that solid cancer and sepsis are linked. The primary objective of this study is to explore this connection further, investigating the causal effect of solid cancer on sepsis by applying Mendelian randomization (MR). Methods Using genome-wide association study (GWAS) data from the Medical Research Council-Integrative Epidemiology Unit database, we conducted a bidirectional two-sample Mendelian randomization (MR) analysis to test the causal association between solid cancers (10 GWAS, 1,345,730 samples) and sepsis (2 GWAS, 1,288,566 samples) in European ancestry. In the context of multivariable MR analysis, lifestyle risk factors such as body mass index (BMI) were incorporated, with relevant clinical interventions taken into account. Results The two-sample MR analysis suggested a causal relationship between renal cancer and sepsis (OR = 1.051, 95% CI = 1.019–1.085, PIVW = 1.800E-03). Renal cancer (OR = 1.064, 95% CI = 1.011–1.120, PIVW = 1.60E-02), BMI (OR = 1.315, 95% CI = 1.176–1.471, PIVW = 1.25E-06), and smoking (OR = 1.139, 95% CI = 1.009–1.286, PIVW = 3.65E-02) showed a significant association with sepsis in our lifestyle multivariable MR analysis. Reverse MR analysis indicates that sepsis may prevent renal cancer. (OR = 0.924, 95% CI = 0.865 -0.988, PIVW = 2.060E-02). Conclusions Our findings suggest renal cancer is correlated with the occurrence of sepsis. This association is partially influenced by BMI and smoking. Unexpectedly, sepsis may act as a protective effect against renal cancer.
- Top Cited PapersOpen Access
A brain-to-lung signal from GABAergic neurons to ADRB2+ interstitial macrophages promotes pulmonary inflammatory responses
- Open Access
- 28 February 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-15
Elevated levels of S100A8 and S100A9 exacerbate muscle mitochondrial fragmentation in sepsis-induced muscle atrophy
Sepsis-induced skeletal muscle atrophy is common in septic patients with the increases risk of mortality and is associated with myocellular mitochondrial dysfunction. Nevertheless, the specific mechanism of sepsis muscle atrophy remains unclear. Here we conducted a clinical retrospective analysis and observed the elevation of skeletal muscle index (ΔSMI) was an independent risk factor for 60-day mortality in septic patients. Moreover, in mouse model of sepsis, the skeletal muscle atrophy was also observed, which was associated with the upregulation of S100a8/a9-mediated mitochondrial dysfunction. Inhibition of S100a8/a9 significantly improved mitochondrial function and alleviated muscle atrophy. Conversely, administration of recombinant S100a8/a9 protein exacerbated mitochondrial energy exhaustion and myocyte atrophy. Mechanistically, S100a8/a9 binding to RAGE induced Drp1 phosphorylation and mitochondrial fragmentation, resulting in muscle atrophy. Additionally, RAGE ablation or administration of Drp1 inhibitor significantly reduced Drp1-mediated mitochondrial fission, improved mitochondrial morphology and function. Our findings indicated the pivotal role of S100a8/a9 in driving the mitochondrial fragmentation in septic muscle atrophy. Targeting S100a8/a9-RAGE-initiated mitochondrial fission might offer a promising therapeutic intervention against septic muscle atrophy.
- 28 February 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-15
Open AccessElevated levels of S100A8 and S100A9 exacerbate muscle mitochondrial fragmentation in sepsis-induced muscle atrophy
Sepsis-induced skeletal muscle atrophy is common in septic patients with the increases risk of mortality and is associated with myocellular mitochondrial dysfunction. Nevertheless, the specific mechanism of sepsis muscle atrophy remains unclear. Here we conducted a clinical retrospective analysis and observed the elevation of skeletal muscle index (ΔSMI) was an independent risk factor for 60-day mortality in septic patients. Moreover, in mouse model of sepsis, the skeletal muscle atrophy was also observed, which was associated with the upregulation of S100a8/a9-mediated mitochondrial dysfunction. Inhibition of S100a8/a9 significantly improved mitochondrial function and alleviated muscle atrophy. Conversely, administration of recombinant S100a8/a9 protein exacerbated mitochondrial energy exhaustion and myocyte atrophy. Mechanistically, S100a8/a9 binding to RAGE induced Drp1 phosphorylation and mitochondrial fragmentation, resulting in muscle atrophy. Additionally, RAGE ablation or administration of Drp1 inhibitor significantly reduced Drp1-mediated mitochondrial fission, improved mitochondrial morphology and function. Our findings indicated the pivotal role of S100a8/a9 in driving the mitochondrial fragmentation in septic muscle atrophy. Targeting S100a8/a9-RAGE-initiated mitochondrial fission might offer a promising therapeutic intervention against septic muscle atrophy.
- 26 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (22) , 1791-1811
Extracellular RIPK3 Acts as a Damage-Associated Molecular Pattern to Exaggerate Cardiac Ischemia/Reperfusion Injury
BACKGROUND: Cardiac ischemia/reperfusion (I/R) injury has emerged as an important therapeutic target for ischemic heart disease. Currently, there is no effective therapy for reducing cardiac I/R injury. Damage-associated molecular patterns are endogenous molecules released after cellular damage to exaggerate tissue inflammation and injury. RIPK3 (receptor-interacting protein kinase 3), a well-established intracellular mediator of cell necroptosis and inflammation, serves as a circulating biomarker of multiple diseases. However, whether extracellular RIPK3 also exerts biological functions in cardiac I/R injury remains totally unknown. METHODS: Patients with acute myocardial infarction receiving percutaneous coronary intervention (PCI) were recruited independently in the discovery cohort (103 patients) and validation cohort (334 patients), and major adverse cardiovascular events were recorded. Plasma samples were collected before and after PCI (6 and 24 h) for RIPK3 concentration measurement. Cultured neonatal rat ventricular myocytes, macrophages and endothelial cells, and in vivo mouse models with myocardial injury induced by I/R (or hypoxia/reoxygenation) were used to investigate the role and mechanisms of extracellular RIPK3. Another cohort including patients with acute myocardial infarction receiving PCI and healthy volunteers was recruited to further explore the mechanisms of extracellular RIPK3. RESULTS: In the discovery cohort, elevated plasma RIPK3 levels after PCI are associated with poorer short- and long-term outcomes in patients with acute myocardial infarction, as confirmed in the validation cohort. In both cultured cells and in vivo mouse models, recombinant RIPK3 protein exaggerated myocardial I/R (or hypoxia/reoxygenation) injury, which was alleviated by the RIPK3 antibody. Mechanistically, RIPK3 acted as a damage-associated molecular pattern and bound with RAGE (receptor of advanced glycation end-products), subsequently activating CaMKII (Ca 2+ /calmodulin-dependent kinase II) to elicit the detrimental effects. The positive correlation between plasma RIPK3 concentrations and CaMKII phosphorylation in human peripheral blood mononuclear cells was confirmed. CONCLUSIONS: We identified the positive relationship between plasma RIPK3 concentrations and the risk of major adverse cardiovascular events in patients with acute myocardial infarction receiving PCI. As a damage-associated molecular pattern, extracellular RIPK3 plays a causal role in multiple pathological conditions during cardiac I/R injury through RAGE/CaMKII signaling. These findings expand our understanding of the physiological and pathological roles of RIPK3, and also provide a promising therapeutic target for myocardial I/R injury and the associated complications.
- 26 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (22) , 1791-1811
Extracellular RIPK3 Acts as a Damage-Associated Molecular Pattern to Exaggerate Cardiac Ischemia/Reperfusion Injury
BACKGROUND: Cardiac ischemia/reperfusion (I/R) injury has emerged as an important therapeutic target for ischemic heart disease. Currently, there is no effective therapy for reducing cardiac I/R injury. Damage-associated molecular patterns are endogenous molecules released after cellular damage to exaggerate tissue inflammation and injury. RIPK3 (receptor-interacting protein kinase 3), a well-established intracellular mediator of cell necroptosis and inflammation, serves as a circulating biomarker of multiple diseases. However, whether extracellular RIPK3 also exerts biological functions in cardiac I/R injury remains totally unknown. METHODS: Patients with acute myocardial infarction receiving percutaneous coronary intervention (PCI) were recruited independently in the discovery cohort (103 patients) and validation cohort (334 patients), and major adverse cardiovascular events were recorded. Plasma samples were collected before and after PCI (6 and 24 h) for RIPK3 concentration measurement. Cultured neonatal rat ventricular myocytes, macrophages and endothelial cells, and in vivo mouse models with myocardial injury induced by I/R (or hypoxia/reoxygenation) were used to investigate the role and mechanisms of extracellular RIPK3. Another cohort including patients with acute myocardial infarction receiving PCI and healthy volunteers was recruited to further explore the mechanisms of extracellular RIPK3. RESULTS: In the discovery cohort, elevated plasma RIPK3 levels after PCI are associated with poorer short- and long-term outcomes in patients with acute myocardial infarction, as confirmed in the validation cohort. In both cultured cells and in vivo mouse models, recombinant RIPK3 protein exaggerated myocardial I/R (or hypoxia/reoxygenation) injury, which was alleviated by the RIPK3 antibody. Mechanistically, RIPK3 acted as a damage-associated molecular pattern and bound with RAGE (receptor of advanced glycation end-products), subsequently activating CaMKII (Ca 2+ /calmodulin-dependent kinase II) to elicit the detrimental effects. The positive correlation between plasma RIPK3 concentrations and CaMKII phosphorylation in human peripheral blood mononuclear cells was confirmed. CONCLUSIONS: We identified the positive relationship between plasma RIPK3 concentrations and the risk of major adverse cardiovascular events in patients with acute myocardial infarction receiving PCI. As a damage-associated molecular pattern, extracellular RIPK3 plays a causal role in multiple pathological conditions during cardiac I/R injury through RAGE/CaMKII signaling. These findings expand our understanding of the physiological and pathological roles of RIPK3, and also provide a promising therapeutic target for myocardial I/R injury and the associated complications.
- Open Access
- 1 August 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 3629-3641
Comparison Between Esketamine and Alfentanil for Hysteroscopy: A Prospective, Double-Blind, Randomized Controlled Trial
Purpose: This study aimed to establish the 95% effective dose (ED95) of esketamine in combination with propofol for hysteroscopy and then to evaluate its efficacy and safety profile. Patients and Methods: This prospective, double-blind, randomized controlled trial consisted of two cohorts. In cohort 1, 45 women aged 18– 65 years undergoing hysteroscopy were randomly assigned to either group E (esketamine + propofol) or group A (alfentanil + propofol). Dixon’s up-and-down method was used to determine the ED95 of esketamine and alfentanil. In cohort 2, 86 patients were randomized to group E and group A, with the calculated ED95 dose of the study drugs used for induction. The success rate of anesthesia using the ED95% dose, along with parameters related to anesthesia induction, recovery, and adverse events were also recorded. Results: The ED95 of esketamine was 0.254 mg/kg (95% CI: 0.214– 1.004), while that of alfentanil was 9.121 μg/kg (95% CI: 8.479– 13.364). The anesthesia success rate was 93.0% in group E and 95.2% in group A (p = 0.664). After resuscitation, both groups achieved a 100% success rate. The induction time was significantly shorter in group E (60.0 [55.0– 70.0] s) compared to group A (67.0 [61.0– 79.3] s) (p = 0.006). Group E had lower rates of respiratory depression (p < 0.001), hypoxia (p = 0.006), minimum perioperative SpO2 (p = 0.010), and hypotension (p = 0.001). Esketamine had less effect on respiratory rate, heart rate, mean blood pressure, and end-tidal carbon dioxide compared to alfentanil (all p < 0.001). There were no significant differences in postoperative pain between the two groups. Conclusion: This study determined the ED 95 dose of esketamine for intravenous general anesthesia during hysteroscopy. Esketamine showed less respiratory and hemodynamic depression, as well as fewer adverse effects compared to alfentanil. Esketamine is an ideal anesthetic agent compared to alfentanil for hysteroscopic anesthesia. Trial Registration: www.chictr.org.cn, (ChiCTR2300077283); registered November 3, 2023.
- 1 August 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 3629-3641
Open AccessComparison Between Esketamine and Alfentanil for Hysteroscopy: A Prospective, Double-Blind, Randomized Controlled Trial
Purpose: This study aimed to establish the 95% effective dose (ED95) of esketamine in combination with propofol for hysteroscopy and then to evaluate its efficacy and safety profile. Patients and Methods: This prospective, double-blind, randomized controlled trial consisted of two cohorts. In cohort 1, 45 women aged 18– 65 years undergoing hysteroscopy were randomly assigned to either group E (esketamine + propofol) or group A (alfentanil + propofol). Dixon’s up-and-down method was used to determine the ED95 of esketamine and alfentanil. In cohort 2, 86 patients were randomized to group E and group A, with the calculated ED95 dose of the study drugs used for induction. The success rate of anesthesia using the ED95% dose, along with parameters related to anesthesia induction, recovery, and adverse events were also recorded. Results: The ED95 of esketamine was 0.254 mg/kg (95% CI: 0.214– 1.004), while that of alfentanil was 9.121 μg/kg (95% CI: 8.479– 13.364). The anesthesia success rate was 93.0% in group E and 95.2% in group A (p = 0.664). After resuscitation, both groups achieved a 100% success rate. The induction time was significantly shorter in group E (60.0 [55.0– 70.0] s) compared to group A (67.0 [61.0– 79.3] s) (p = 0.006). Group E had lower rates of respiratory depression (p < 0.001), hypoxia (p = 0.006), minimum perioperative SpO2 (p = 0.010), and hypotension (p = 0.001). Esketamine had less effect on respiratory rate, heart rate, mean blood pressure, and end-tidal carbon dioxide compared to alfentanil (all p < 0.001). There were no significant differences in postoperative pain between the two groups. Conclusion: This study determined the ED 95 dose of esketamine for intravenous general anesthesia during hysteroscopy. Esketamine showed less respiratory and hemodynamic depression, as well as fewer adverse effects compared to alfentanil. Esketamine is an ideal anesthetic agent compared to alfentanil for hysteroscopic anesthesia. Trial Registration: www.chictr.org.cn, (ChiCTR2300077283); registered November 3, 2023.
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 21 (10) , 1852-1865
Bibliometric Analysis of TREM2 (2001-2022): Trends, Hotspots and Prospects in Human Disease
Background: Triggering receptor expressed in myeloid cells 2 (TREM2), a transmembrane receptor, has garnered extensive research attention due to its pivotal role in the diagnosis and treatment of various diseases. Despite the abundance of studies on its function, there is a gap in comprehensive analysis and summarization of the current state of this research field.
- 1 January 2024
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 21 (10) , 1852-1865
Open AccessBibliometric Analysis of TREM2 (2001-2022): Trends, Hotspots and Prospects in Human Disease
Background: Triggering receptor expressed in myeloid cells 2 (TREM2), a transmembrane receptor, has garnered extensive research attention due to its pivotal role in the diagnosis and treatment of various diseases. Despite the abundance of studies on its function, there is a gap in comprehensive analysis and summarization of the current state of this research field.
- Top Cited Papers
- 15 February 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (4)
TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis
Sepsis is a leading cause of death in critical illness, and its pathophysiology varies depending on preexisting medical conditions. Here we identified nonalcoholic fatty liver disease (NAFLD) as an independent risk factor for sepsis in a large clinical cohort and showed a link between mortality in NAFLD-associated sepsis and hepatic mitochondrial and energetic metabolism dysfunction. Using in vivo and in vitro models of liver lipid overload, we discovered a metabolic coordination between hepatocyte mitochondria and liver macrophages that express triggering receptor expressed on myeloid cells-2 (TREM2). Trem2-deficient macrophages released exosomes that impaired hepatocytic mitochondrial structure and energy supply because of their high content of miR-106b-5p, which blocks Mitofusin 2 (Mfn2). In a mouse model of NAFLD-associated sepsis, TREM2 deficiency accelerated the initial progression of NAFLD and subsequent susceptibility to sepsis. Conversely, overexpression of TREM2 in liver macrophages improved hepatic energy supply and sepsis outcome. This study demonstrates that NAFLD is a risk factor for sepsis, providing a basis for precision treatment, and identifies hepatocyte-macrophage metabolic coordination and TREM2 as potential targets for future clinical trials.
- 15 February 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (4)
Top Cited PapersTREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis
Sepsis is a leading cause of death in critical illness, and its pathophysiology varies depending on preexisting medical conditions. Here we identified nonalcoholic fatty liver disease (NAFLD) as an independent risk factor for sepsis in a large clinical cohort and showed a link between mortality in NAFLD-associated sepsis and hepatic mitochondrial and energetic metabolism dysfunction. Using in vivo and in vitro models of liver lipid overload, we discovered a metabolic coordination between hepatocyte mitochondria and liver macrophages that express triggering receptor expressed on myeloid cells-2 (TREM2). Trem2-deficient macrophages released exosomes that impaired hepatocytic mitochondrial structure and energy supply because of their high content of miR-106b-5p, which blocks Mitofusin 2 (Mfn2). In a mouse model of NAFLD-associated sepsis, TREM2 deficiency accelerated the initial progression of NAFLD and subsequent susceptibility to sepsis. Conversely, overexpression of TREM2 in liver macrophages improved hepatic energy supply and sepsis outcome. This study demonstrates that NAFLD is a risk factor for sepsis, providing a basis for precision treatment, and identifies hepatocyte-macrophage metabolic coordination and TREM2 as potential targets for future clinical trials.